Home・Akciju saraksts・AbbVie Inc

AbbVie Inc

Atvērts

SektorsVeselības aprūpe

249.89 0.87

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

247

Max

250.75

Galvenie mērījumi
By Trading Economics
Ienākumi	2.9B 3.6B
Pārdošana	2B 17B
P/E Sektora vidējais	69.459 57.002
EPS	3.65
Dividenžu ienesīgums	2.78
Peļņas marža	21.283
Darbinieki	57,000
EBITDA	3B 6.7B

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+11.8% upside

Dividendes
By Acuity
Dividenžu ienesīgums Sektora vidējais	2.78% 2.22%
Nākamie ieņēmumi	2026. g. 30. okt.
Nākamais dividenžu datums	2026. g. 14. aug.
Nākamais Ex dividenžu datums	2026. g. 14. okt.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-16B 438B
Iepriekšējā atvēršanas cena	249.02
Iepriekšējā slēgšanas cena	249.89

Ziņu noskaņojums

By Acuity

54%

46%

263 / 340 Rangs Healthcare

AbbVie Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 11. aug. 20:06 UTC

News

AbbVie shares are higher as BNP Paribas raises the price target to $247. Allergan Aesthetics enhances its Partner Privileges program to boost customer engagement.

2026. g. 10. aug. 23:06 UTC

AbbVie Inc shares are lower in after-market hours amid mixed market sentiment influenced by geopolitical tensions and President Trump's comments on economic pressure.

2026. g. 7. aug. 23:01 UTC

AbbVie Inc shares are trading lower in after-market hours, with no specific news identified to explain the decline. The stock remains near its one-month low.

2026. g. 6. aug. 20:06 UTC

Social Media

AbbVie Inc shares are lower as bearish sentiment grows in biotech and pharma sectors, with discussions highlighting potential resistance and negative momentum patterns.

2026. g. 5. aug. 19:26 UTC

News

Event

AbbVie shares are higher as Canada's Drug Agency recommends UBRELVY for migraine treatment. The company also raised its 2026 revenue outlook to $67.60 billion.

2026. g. 4. aug. 23:01 UTC

Event

AbbVie Inc shares are higher in after-market hours following a recommendation for UBRELVY® reimbursement by Canada's Drug Agency, enhancing patient accessibility.

2026. g. 3. aug. 23:06 UTC

News

Canaccord Genuity raised its price target for AbbVie to $290, contributing to a modest increase in shares during after-market hours.

2026. g. 31. jūl. 20:04 UTC

News

Event

AbbVie Inc. lowered its 2026 adjusted earnings guidance, now projecting $13.87 to $14.07 per share, contributing to a decline in its stock price today.

2026. g. 30. jūl. 22:41 UTC

Social Media

Event

AbbVie Inc announced JUVÉDERM® Day for August 19, 2026, boosting shares higher in after-market hours amid strong trading activity.

2026. g. 29. jūl. 23:06 UTC

Event

The European Commission approved RINVOQ® for severe alopecia areata, contributing to higher after-market hours trading for Abbvie Inc. Shares remain above their 20-day moving average.

2026. g. 28. jūl. 23:06 UTC

AbbVie Inc. shares traded higher in after-market hours, remaining above the 20-day moving average and near the upper end of their one-month range.

2026. g. 27. jūl. 19:46 UTC

Social Media

AbbVie Inc. shares are trading lower amid a broader market decline, influenced by falling crude oil prices despite recent social media discussions on its 52-week high.

2026. g. 24. jūl. 23:51 UTC

Social Media

Abbvie shares are trading lower in after-market hours despite a presentation on ABBV-CLS-484, a novel cancer immunotherapy inhibitor.

2026. g. 23. jūl. 10:16 UTC

AbbVie Inc shares are trading lower in pre-market hours, with no specific news identified to explain the movement. The stock remains within its one-month trading range.

2026. g. 22. jūl. 23:06 UTC

AbbVie Inc shares are modestly higher in after-market trading. No specific news was identified to explain the movement, amid broader market volatility.

2026. g. 21. jūl. 19:06 UTC

Abbvie Inc. is higher today, supported by broader market gains and optimism in the semiconductor sector after TSMC's potential price increases by 2027.

2026. g. 20. jūl. 23:01 UTC

AbbVie Inc. shares are lower in after-hours trading following a decline from earlier gains, remaining above the 20-day moving average.

Salīdzinājums

Cenas izmaiņa

AbbVie Inc Prognoze

Cenas mērķis

By TipRanks

11.8% augšup

Prognoze 12 mēnešiem

Vidējais 277.24 USD 11.8%

Augstākais 300 USD

Zemākais 225 USD

Pamatojoties uz 23 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi AbbVie Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

23 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 23 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam AbbVie Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

263 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.